Development of a high-throughput screening cancer cell-based luciferase refolding assay for identifying Hsp90 inhibitors

Assay and Drug Development Technologies

Volumn 11, Issue 8, 2013, Pages 478-488

  Sadikot, Takrima ^a,b   Swink, Megan ^a   Eskew, Jeffery D ^a   Brown, Douglas ^a   Zhao, Huiping ^c   Kusuma, Bhaskar R ^c   Rajewski, Roger A ^d   Blagg, Brian S J ^c   Matts, Robert L ^e   Holzbeierlein, Jeffrey M ^a   Vielhauer, George A ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b WASHBURN UNIVERSITY   (United States)

^c Departments of Biology and Medicinal Chemistry   (United States)

^d UNIVERSITY OF KANSAS   (United States)

^e OKLAHOMA STATE UNIVERSITY   (United States)

Author keywords

ABC; ATP binding cassette; counts per second; cps; FBS; fetal bovine serum; heat shock protein 90; heat shock response; Hsp90; HSR; HTS, highthroughput; rabbit reticulocyte lysate; RRL; S N; screening; signal to noise ratio; SRB; sulforhodamine B

Indexed keywords

BIPERIDEN; CHAPERONE; ETHOXYQUIN; HEAT SHOCK PROTEIN 90 INHIBITOR; LUCIFERASE; NOVOBIOCIN; ONCOPROTEIN; ANTINEOPLASTIC AGENT; COLORING AGENT; ENZYME INHIBITOR; HEAT SHOCK PROTEIN 90; LISSAMINE RHODAMINE B; MOLECULAR LIBRARY; RHODAMINE;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER THERAPY; COLON CANCER; DOSE RESPONSE; DRUG STRUCTURE; ENZYME INHIBITION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; LUNG CANCER; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN FOLDING; RETICULOCYTE; SIGNAL NOISE RATIO; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOASSAY; CHEMISTRY; DRUG EFFECTS; METABOLISM; MOLECULAR LIBRARY; PROCEDURES; PROTEIN DENATURATION; PROTEIN REFOLDING; RABBIT; SYNTHESIS; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL ASSAY; BLOTTING, WESTERN; CELL LINE, TUMOR; COLORING AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HIGH-THROUGHPUT SCREENING ASSAYS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LUCIFERASES; NOVOBIOCIN; PROTEIN DENATURATION; PROTEIN REFOLDING; RABBITS; RETICULOCYTES; RHODAMINES; SMALL MOLECULE LIBRARIES;

EID: 84886405298     PISSN: 1540658X     EISSN: 15578127     Source Type: Journal    
DOI: 10.1089/adt.2012.498     Document Type: Article

References (37)

1. Chiosis G, Huezo H, Rosen N, et al.: 17AAG: low target binding affinity and potent cell activity-finding an explanation. Mol Cancer Ther 2003;2:123-129.
2. Travers J, Sharp S, Workman P: HSP90 inhibition: two-pronged exploitation of cancer dependencies. Drug Discov Today 2012;17:242-252.
3. Neckers L, Workman P: Hsp90 molecular chaperone inhibitors: are we there yet Clin Cancer Res 2012;18:64-76.
4. Kummar S, Gutierrez ME, Gardner ER, et al.: Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies. Eur J Cancer 2010;46:340-347.
5. Kim YS, Alarcon SV, Lee S, et al.: Update on Hsp90 inhibitors in clinical trial. Curr Top Med Chem 2009;9:1479-1492.
6. Burlison JA, Avila C, Vielhauer G, et al.: Development of novobiocin analogues that manifest anti-proliferative activity against several cancer cell lines. J Org Chem 2008;73:2130-2137. (Pubitemid 351497740)
7. Burlison JA, Blagg BS: Synthesis and evaluation of coumermycin A1 analogues that inhibit the Hsp90 protein folding machinery. Org Lett 2006;8:4855-4858. (Pubitemid 44629477)
8. Donnelly AC, Mays JR, Burlison JA, et al.: The design, synthesis, and evaluation of coumarin ring derivatives of the novobiocin scaffold that exhibit antiproliferative activity. J Org Chem 2008;73:8901-8920.
9. Eskew JD, Sadikot T, Morales P, et al.: Development and characterization of a novel C-terminal inhibitor of Hsp90 in androgen dependent and independent prostate cancer cells. BMC Cancer 2011;11:468-484.
10. Yu XM, Shen G, Neckers L, et al.: Hsp90 inhibitors identified from a library of novobiocin analogues. J Am Chem Soc 2005;127:12778-12779. (Pubitemid 41339147)
11. Zhao H, Brandt GE, Galam L, Matts RL, Blagg BS: Identification and initial SAR of silybin: an Hsp90 inhibitor. Bioorg Med Chem Lett 2011;21:2659-2664.
12. Kusuma BR, Duerfeldt AS, Blagg BS: Synthesis and biological evaluation of arylated novobiocin analogs as Hsp90 inhibitors. Bioorg Med Chem Lett 2011;21:7170-7174.
13. Kusuma BR, Peterson LB, Zhao H, et al.: Targeting the heat shock protein 90 dimer with dimeric inhibitors. J Med Chem 2011;54:6234-6253.
14. Marcu MG, Chadli A, Bouhouche I, Catelli M, Neckers LM: The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATPbinding domain in the carboxyl terminus of the chaperone. J Biol Chem 2000;275:37181-37186. (Pubitemid 32002137)
15. Matthews SB, Vielhauer GA, Manthe CA, et al.: Characterization of a novel novobiocin analogue as a putative C-terminal inhibitor of heat shock protein 90 in prostate cancer cells. Prostate 2010;70:27-36.
16. Matts RL, Manjarrez JR: Assays for identification of Hsp90 inhibitors and biochemical methods for discriminating their mechanism of action. Curr Top Med Chem 2009;9:1462-1478.
17. Nguyen VT, Morange M, Bensaude O: Protein denaturation during heat shock and related stress. Escherichia coli beta-galactosidase and Photinus pyralis luciferase inactivation in mouse cells. J Biol Chem 1989;264:10487-10492. (Pubitemid 19161613)
18. Pinto M, Morange M, Bensaude O: Denaturation of proteins during heat shock. In vivo recovery of solubility and activity of reporter enzymes. J Biol Chem 1991;266:13941-13946. (Pubitemid 21907444)
19. Dubois MF, Hovanessian AG, Bensaude O: Heat-shock-induced denaturation of proteins. Characterization of the insolubilization of the interferon-induced p68 kinase. J Biol Chem 1991;266:9707-9711. (Pubitemid 21906714)
20. Schumacher RJ, Hurst R, Sullivan WP, et al.: ATP-dependent chaperoning activity of reticulocyte lysate. J Biol Chem 1994;269:9493-9499. (Pubitemid 24196541)
21. Forreiter C, Kirschner M, Nover L: Stable transformation of an Arabidopsis cell suspension culture with firefly luciferase providing a cellular system for analysis of chaperone activity in vivo. Plant Cell 1997;9:2171-2181. (Pubitemid 28174054)
22. Souren JE, Wiegant FA, van Hof P, van Aken JM, van Wijk R: The effect of temperature and protein synthesis on the renaturation of firefly luciferase in intact H9c2 cells. Cell Mol Life Sci 1999;55:1473-1481. (Pubitemid 29427946)
23. Souren JE, Wiegant FA, Van Wijk R: The role of hsp70 in protection and repair of luciferase activity in vivo; experimental data and mathematical modelling. Cell Mol Life Sci 1999;55:799-811. (Pubitemid 29257628)
24. Galam L, Hadden MK, Ma Z, et al.: High-throughput assay for the identification of Hsp90 inhibitors based on Hsp90-dependent refolding of firefly luciferase. Bioorg Med Chem 2007;15:1939-1946. (Pubitemid 46188404)
25. Kamal A, Thao L, Sensintaffar J, et al.: A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 2003;425: 407-410. (Pubitemid 37187270)
26. Moulick K, Ahn JH, Zong H, et al.: Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90. Nat Chem Biol 2011; 7:818-826.
27. Kimbrel EA, Davis TN, Bradner JE, Kung AL: In vivo pharmacodynamic imaging of proteasome inhibition. Mol Imaging 2009;8:140-147.
28. Kasibhatla SR, Hong K, Biamonte MA, et al.: Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity. J Med Chem 2007;50:2767-2778. (Pubitemid 46980848)
29. Lundgren K, Zhang H, Brekken J, et al.: BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90. Mol Can Ther 2009;8:921-929.
30. Eccles SA, Massey A, Raynaud FI, et al.: NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res 2008;68:2850-2860. (Pubitemid 351556284)
31. Salehi AH, Morris SJ, Ho WC, et al.: AEG3482 is an antiapoptotic compound that inhibits Jun kinase activity and cell death through induced expression of heat shock protein 70. Chem Biol 2006;13:213-223. (Pubitemid 43255593)
32. Samadi AK, Zhang X, Mukerji R, et al.: A novel C-terminal HSP90 inhibitor KU135 induces apoptosis and cell cycle arrest in melanoma cells. Cancer Lett 2011;312:158-167.
33. Senju M, Sueoka N, Sato A, et al.: Hsp90 inhibitors cause G2/M arrest associated with the reduction of Cdc25C and Cdc2 in lung cancer cell lines. J Cancer Res Clin Oncol 2006;132:150-158. (Pubitemid 43015775)
34. Hernandez A, Lopez-Lluch G, Bernal JA, Navas P, Pintor-Toro JA: Dicoumarol down-regulates human PTTG1/Securin mRNA expression through inhibition of Hsp90. Mol Can Ther 2008;7:474-482. (Pubitemid 351482130)
35. Schneider C, Sepp-Lorenzino L, Nimmesgern E, et al.: Pharmacologic shifting of a balance between protein refolding and degradation mediated by Hsp90. Proc Natl Acad Sci USA 1996;93:14536-14541. (Pubitemid 26419002)
36. Minami M, Nakamura M, Emori Y, Minami Y: Both the N-and C-terminal chaperone sites of Hsp90 participate in protein refolding. Eur J Biochem 2001;268:2520-2524. (Pubitemid 32417781)
37. Gupta R, Kasturi P, Bracher A, et al.: Firefly luciferase mutants as sensors of proteome stress. Nat Methods 2011;8:879-884.